Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMSES: Right ventricular remodeling with ambrisentan + PDE-5 inhibitor in pulmonary arterial hypertension
2016-004806-32Phase 4Terminated
- Sponsor
- Italian Pulmonary Hypertension Network
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ambrisentan in pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH), sponsored by Italian Pulmonary Hypertension Network. Primary endpoints: Right ventricular reverse remodeling and Hemodynamic improvement. Started May 2021; status: terminated.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2016-004806-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004806-32.